Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
In this open-label, randomized, prospective clinical trial, nucleophosmin-1(NPM1) mutated
acute myeloid leukemia (AML) patients who have reached CR are randomized into two groups.The
control group receive high-dose cytarabine(HDAC) regimen while the experimental group receive
high dose of cytarabine plus tretinoin(ATRA) and arsenic trioxide(ATO) treatment.The safety
and efficacy of ATRA and ATO is evaluated.